Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitin...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2021-04, Vol.72 (7), p.1247-1250 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1250 |
|---|---|
| container_issue | 7 |
| container_start_page | 1247 |
| container_title | Clinical infectious diseases |
| container_volume | 72 |
| creator | Titanji, Boghuma K Farley, Monica M Mehta, Ashish Connor-Schuler, Randi Moanna, Abeer Cribbs, Sushma K O’Shea, Jesse DeSilva, Kathryn Chan, Bonnie Edwards, Alex Gavegnano, Christina Schinazi, Raymond F Marconi, Vincent C |
| description | Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials. |
| doi_str_mv | 10.1093/cid/ciaa879 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7337637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciaa879</oup_id><sourcerecordid>2418726586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-3a94fd3bc6d53925cd8f0ce05833ac5b2f5a98330a24ec0c7c60d4e5ddce80203</originalsourceid><addsrcrecordid>eNp9kU1LAzEQhoMotlZP3iUnEWQ1H5vd7EXQ-gmKghaPIc3O2ki7qUm24L830lr04iFkyDw8GeZFaJ-SE0oqfmpsnY7Wsqw2UJ8KXmaFqOhmqomQWS657KGdEN4JoVQSsY16nImqzIuijx5HAbBr8IX21thoWzvGtsVPOlpoY8CvNk7wg6vB6wg4OvwMC_CAh867Vi-s7wK-tAF00jBCq1201ehpgL3VPUCj66uX4W12_3hzNzy_z0xOWcy4rvKm5mNT1IJXTJhaNsRAmpdzbcSYNUJXqSaa5WCIKU1B6hxEXRuQhBE-QGdL77wbzyC9ttHrqZp7O9P-Uzlt1d9OayfqzS1UyXlZ8DIJjlYC7z46CFHNbDAwneoWXBcUy6ksWSFkkdDjJWq8C8FDs_6GEvUdgUoRqFUEiT74Pdma_dl5Ag6XgOvm_5q-AC9OkJs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2418726586</pqid></control><display><type>article</type><title>Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Titanji, Boghuma K ; Farley, Monica M ; Mehta, Ashish ; Connor-Schuler, Randi ; Moanna, Abeer ; Cribbs, Sushma K ; O’Shea, Jesse ; DeSilva, Kathryn ; Chan, Bonnie ; Edwards, Alex ; Gavegnano, Christina ; Schinazi, Raymond F ; Marconi, Vincent C</creator><creatorcontrib>Titanji, Boghuma K ; Farley, Monica M ; Mehta, Ashish ; Connor-Schuler, Randi ; Moanna, Abeer ; Cribbs, Sushma K ; O’Shea, Jesse ; DeSilva, Kathryn ; Chan, Bonnie ; Edwards, Alex ; Gavegnano, Christina ; Schinazi, Raymond F ; Marconi, Vincent C</creatorcontrib><description>Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa879</identifier><identifier>PMID: 32597466</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antiviral Agents - therapeutic use ; Azetidines ; Brief Reports ; COVID-19 - drug therapy ; Humans ; Purines ; Pyrazoles ; Retrospective Studies ; SARS-CoV-2 ; Sulfonamides ; Treatment Outcome</subject><ispartof>Clinical infectious diseases, 2021-04, Vol.72 (7), p.1247-1250</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020. 2020</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-3a94fd3bc6d53925cd8f0ce05833ac5b2f5a98330a24ec0c7c60d4e5ddce80203</citedby><cites>FETCH-LOGICAL-c412t-3a94fd3bc6d53925cd8f0ce05833ac5b2f5a98330a24ec0c7c60d4e5ddce80203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32597466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Titanji, Boghuma K</creatorcontrib><creatorcontrib>Farley, Monica M</creatorcontrib><creatorcontrib>Mehta, Ashish</creatorcontrib><creatorcontrib>Connor-Schuler, Randi</creatorcontrib><creatorcontrib>Moanna, Abeer</creatorcontrib><creatorcontrib>Cribbs, Sushma K</creatorcontrib><creatorcontrib>O’Shea, Jesse</creatorcontrib><creatorcontrib>DeSilva, Kathryn</creatorcontrib><creatorcontrib>Chan, Bonnie</creatorcontrib><creatorcontrib>Edwards, Alex</creatorcontrib><creatorcontrib>Gavegnano, Christina</creatorcontrib><creatorcontrib>Schinazi, Raymond F</creatorcontrib><creatorcontrib>Marconi, Vincent C</creatorcontrib><title>Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Azetidines</subject><subject>Brief Reports</subject><subject>COVID-19 - drug therapy</subject><subject>Humans</subject><subject>Purines</subject><subject>Pyrazoles</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Sulfonamides</subject><subject>Treatment Outcome</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1LAzEQhoMotlZP3iUnEWQ1H5vd7EXQ-gmKghaPIc3O2ki7qUm24L830lr04iFkyDw8GeZFaJ-SE0oqfmpsnY7Wsqw2UJ8KXmaFqOhmqomQWS657KGdEN4JoVQSsY16nImqzIuijx5HAbBr8IX21thoWzvGtsVPOlpoY8CvNk7wg6vB6wg4OvwMC_CAh867Vi-s7wK-tAF00jBCq1201ehpgL3VPUCj66uX4W12_3hzNzy_z0xOWcy4rvKm5mNT1IJXTJhaNsRAmpdzbcSYNUJXqSaa5WCIKU1B6hxEXRuQhBE-QGdL77wbzyC9ttHrqZp7O9P-Uzlt1d9OayfqzS1UyXlZ8DIJjlYC7z46CFHNbDAwneoWXBcUy6ksWSFkkdDjJWq8C8FDs_6GEvUdgUoRqFUEiT74Pdma_dl5Ag6XgOvm_5q-AC9OkJs</recordid><startdate>20210408</startdate><enddate>20210408</enddate><creator>Titanji, Boghuma K</creator><creator>Farley, Monica M</creator><creator>Mehta, Ashish</creator><creator>Connor-Schuler, Randi</creator><creator>Moanna, Abeer</creator><creator>Cribbs, Sushma K</creator><creator>O’Shea, Jesse</creator><creator>DeSilva, Kathryn</creator><creator>Chan, Bonnie</creator><creator>Edwards, Alex</creator><creator>Gavegnano, Christina</creator><creator>Schinazi, Raymond F</creator><creator>Marconi, Vincent C</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210408</creationdate><title>Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019</title><author>Titanji, Boghuma K ; Farley, Monica M ; Mehta, Ashish ; Connor-Schuler, Randi ; Moanna, Abeer ; Cribbs, Sushma K ; O’Shea, Jesse ; DeSilva, Kathryn ; Chan, Bonnie ; Edwards, Alex ; Gavegnano, Christina ; Schinazi, Raymond F ; Marconi, Vincent C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-3a94fd3bc6d53925cd8f0ce05833ac5b2f5a98330a24ec0c7c60d4e5ddce80203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Azetidines</topic><topic>Brief Reports</topic><topic>COVID-19 - drug therapy</topic><topic>Humans</topic><topic>Purines</topic><topic>Pyrazoles</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Sulfonamides</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Titanji, Boghuma K</creatorcontrib><creatorcontrib>Farley, Monica M</creatorcontrib><creatorcontrib>Mehta, Ashish</creatorcontrib><creatorcontrib>Connor-Schuler, Randi</creatorcontrib><creatorcontrib>Moanna, Abeer</creatorcontrib><creatorcontrib>Cribbs, Sushma K</creatorcontrib><creatorcontrib>O’Shea, Jesse</creatorcontrib><creatorcontrib>DeSilva, Kathryn</creatorcontrib><creatorcontrib>Chan, Bonnie</creatorcontrib><creatorcontrib>Edwards, Alex</creatorcontrib><creatorcontrib>Gavegnano, Christina</creatorcontrib><creatorcontrib>Schinazi, Raymond F</creatorcontrib><creatorcontrib>Marconi, Vincent C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Titanji, Boghuma K</au><au>Farley, Monica M</au><au>Mehta, Ashish</au><au>Connor-Schuler, Randi</au><au>Moanna, Abeer</au><au>Cribbs, Sushma K</au><au>O’Shea, Jesse</au><au>DeSilva, Kathryn</au><au>Chan, Bonnie</au><au>Edwards, Alex</au><au>Gavegnano, Christina</au><au>Schinazi, Raymond F</au><au>Marconi, Vincent C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-04-08</date><risdate>2021</risdate><volume>72</volume><issue>7</issue><spage>1247</spage><epage>1250</epage><pages>1247-1250</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32597466</pmid><doi>10.1093/cid/ciaa879</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2021-04, Vol.72 (7), p.1247-1250 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7337637 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antiviral Agents - therapeutic use Azetidines Brief Reports COVID-19 - drug therapy Humans Purines Pyrazoles Retrospective Studies SARS-CoV-2 Sulfonamides Treatment Outcome |
| title | Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A47%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Baricitinib%20in%20Patients%20With%20Moderate%20to%20Severe%20Coronavirus%20Disease%202019&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Titanji,%20Boghuma%20K&rft.date=2021-04-08&rft.volume=72&rft.issue=7&rft.spage=1247&rft.epage=1250&rft.pages=1247-1250&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa879&rft_dat=%3Cproquest_pubme%3E2418726586%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2418726586&rft_id=info:pmid/32597466&rft_oup_id=10.1093/cid/ciaa879&rfr_iscdi=true |